Aarti Pharmalabs announced the unaudited financial results for the quarter and nine months ended December 31, 2025, following a Board meeting on February 09, 2026. Key approvals included the financial results, the auditor’s report, and the declaration of an Interim Dividend of ₹1.50 per share (30%) for FY 2025-26. The Board meeting concluded at 07:00 p.m. after commencing at 2:00 p.m. The Record Date for the dividend is set for February 16, 2026.
Unaudited Financial Performance Highlights (Q3 FY2026)
The Board of Directors of Aarti Pharmalabs Limited, during their meeting held on Monday, February 09, 2026, sanctioned the Unaudited Financial Results for the period ending December 31, 2025, covering both standalone and consolidated figures.
Standalone Results Snapshot (Standalone Results)
Reviewing the 3 months ended December 31, 2025, compared to the previous quarter:
- Total Income: Increased to ₹42,488.16 lakhs (from ₹48,288.30 lakhs in Q2 FY26, noting an unusual prior period figure, compared to Q3 FY25’s ₹47,094.72 lakhs).
- Net Profit/(loss) for the period: Stood at ₹4,384.46 lakhs.
- Earnings Per Share (Basic): Reported at ₹4.84.
For the nine months ended December 31, 2025:
- Net Profit/(loss) for the period: Reported at ₹12,599.44 lakhs.
- Earnings Per Share (Basic): Reported at ₹13.90.
Consolidated Results Snapshot (Consolidated Results)
For the 3 months ended December 31, 2025:
- Total Income: Reported at ₹43,190.15 lakhs.
- Net Profit/(loss) for the period attributable to Owners of the Company: Stood at ₹4,795.56 lakhs.
- Earnings Per Share (Basic): Reported at ₹5.29.
For the nine months ended December 31, 2025:
- Net Profit/(loss) for the period attributable to Owners of the Company: Stood at ₹12,540.67 lakhs.
- Earnings Per Share (Basic): Reported at ₹13.84.
Interim Dividend Declaration
The Board formally approved the declaration of an Interim Dividend of ₹1.50 per Equity Share (representing 30% on the face value of ₹5/- each) for the Financial Year 2025-26. The specified ‘Record Date’ for entitlement is Monday, February 16, 2026.
Key Notes and Disclosures
Management provided context regarding specific items impacting the standalone results:
- Stock in Transit: Revenue amounting to ₹4,935 lakhs for goods shipped in Q3 FY26, but not yet delivered by the cutoff date, was excluded from current period revenue and recorded as ‘Stock in Transit’ valued at ₹3,015 Lakhs. These goods reached their destination in Q4.
- Labour Codes Impact: An incremental provision of ₹279.49 Lakhs was made to account for the impact of new labour codes notified by the Government of India on November 21, 2025, treated under exceptional items.
Auditor’s Review Summary
The independent auditors issued a Limited Review Report on the results. In the standalone review, the auditors noted the treatment of the export transaction (Item 3). For the consolidated review, the auditors’ conclusion was based on their review, the audit reports of subsidiaries, and the review report of the joint venture, Ganesh Polychem Limited (consolidated effective 1st April 2025). The auditors’ opinion was not modified regarding these matters.
Source: BSE
